Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis

Rheumatology

Volumn 45, Issue SUPPL. 3, 2006, Pages

  Sunderkötter, Cord ^b   Riemekasten, G ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2C ADRENERGIC RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; FASUDIL; ILOPROST; PHOSPHODIESTERASE INHIBITOR; RHO KINASE;

AMPUTATION; ARTERIOLE; ARTICLE; CLINICAL FEATURE; COLD EXPOSURE; CYANOSIS; DIGITAL ARTERY; DISEASE COURSE; DISEASE SEVERITY; EMOTIONAL STRESS; GANGRENE; HUMAN; HYPEREMIA; HYPOTHESIS; ISCHEMIA; MEDICAL DECISION MAKING; PALLOR; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RECURRENT DISEASE; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; VASCULAR DISEASE; VASOCONSTRICTION; VASODILATATION; VASOSPASM;

FIBROSIS; FINGERS; HUMANS; ISCHEMIA; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SKIN; VASOCONSTRICTION; VASODILATION;

EID: 33748654917     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel280     Document Type: Article

References (15)

1. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996;22:675-94.
2. Furspan PB, Chatterjee S, Mayes MD, Freedman RR. Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon. Rheumatology 2005;44:488-94.
3. Chotani MA, Flavahan S, Mitra S, Daunt D, Flavahan NA. Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000;278:H1075-83.
4. Flavahan NA, Flavahan S, Liu Q et al. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000;43:1886-90.
5. Bailey SR, Eid AH, Mitra S, Flavahan S, Flavahan NA. Rho kinase mediates cold-induced constriction of cutaneous arteries: Role of alpha2C-adrenoceptor translocation. Circ Res 2004;94:1367-74.
6. Boin F, Wigley FM. Understanding, assessing and treating Raynaud's phenomenon. Curr Opin Rheumatol 2005;17:752-60.
7. Wise RA, Wigley FM, White B et al. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: A single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 2004;50:3994-4001.
8. Rajagopalan S, Pfenninger D, Kehrer C et al. Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: Implications for vascular dysfunction and progression of disease. Arthritis Rheum 2003;48:1992-2000.
9. Smyth AE, Bell AL, Bruce IN, McGrann S, Allen JA. Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon. Ann Rheum Dis 2000;59:870-4.
10. Knock GA, Terenghi G, Bunker CB, Bull HA, Dowd PM, Polak JM. Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis. J Invest Dermatol 1993;101:73-8.
11. Steen VD, Costantino JP, Shapiro AP, Medsger TA,Jr. Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990;113:352-7.
12. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
13. Challenor VF, Waller DG, Hayward RA, Griffin MJ, Roath OS. Subjective and objective assessment of enalapril in primary Raynaud's phenomenon. Br J Clin Pharmacol 1991;31:477-80.
14. Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology 2005;44:587-96.
15. Sunderkotter C, Seeliger S, Schonlau F et al. Different pathways leading to cutaneous leukocytoclastic vasculitis in mice. Exp Dermatol 2001;10:391-404.